Aubrey de Grey

Dr Aubrey de Grey is a biomedical gerontologist who transforms our understanding of ageing from an inevitable decline into a solvable scientific challenge. As founder, President and Chief Science Officer of LEV Foundation, he leads the groundbreaking Robust Mouse Rejuvenation study, testing combinations of proven therapies to achieve synergistic lifespan extension, and has recently partnered with Human Longevity, Inc. to decode the biological drivers of exceptional longevity. A Cambridge-educated scientist with degrees in computer science and biology, he is a Fellow of both the Gerontological Society of America and the American Aging Association. Audiences leave his sessions with a radically optimistic yet scientifically grounded perspective on how rejuvenation research can extend healthy human lifespan within our lifetime.

When Dr Aubrey de Grey founded the LEV Foundation, he set out to answer a question that had long frustrated the scientific community: could proven rejuvenation therapies work together to achieve something far greater than the sum of their parts? As founder, President and Chief Science Officer of this biomedical research and advocacy charity based in Silicon Valley, he now leads the Robust Mouse Rejuvenation study, a landmark experiment testing combinations of therapies that have each individually extended lifespan in mice. The study's initial phase, completed in early 2025, delivered what he describes as a qualified win, and the next stage, involving 2,000 mice and eight carefully selected interventions, promises to push the boundaries of what rejuvenation science can achieve. His recent strategic collaboration with Human Longevity, Inc. adds another dimension to this work, combining his research into cellular damage repair with cutting-edge analysis of the biological drivers behind exceptional human longevity.

Cambridge educated with degrees in computer science and biology, Dr de Grey has built his career on a rigorous, evidence-based approach to combating the ageing process. He serves as Editor-in-Chief of Rejuvenation Research, the world's highest-impact peer-reviewed journal focused on intervention in ageing, and his research centres on characterising the cellular and molecular damage that constitutes mammalian ageing and designing practical interventions to repair it. As a Fellow of both the Gerontological Society of America and the American Aging Association, he sits on the editorial and scientific advisory boards of numerous journals and organisations. His work spans laboratory research, clinical trial design, and the development of new biomarkers, positioning him at the intersection of fundamental science and therapeutic application. He delivers 40 to 50 invited talks annually at scientific conferences, universities, pharmaceutical companies, life insurance firms, and public events worldwide.

Dr de Grey equips audiences with a scientifically grounded yet optimistic understanding of how rejuvenation research can extend healthy human lifespan within our lifetime. He translates complex molecular biology into actionable insights for leaders across healthcare, insurance, investment, and policy, helping organisations anticipate and prepare for the profound societal implications of extended healthspan. His presentations move beyond abstract theory to demonstrate the real progress being made in laboratories today, from synergistic therapy combinations to AI-driven biomarkers that quantify ageing. Audiences leave with clarity on the current state of longevity science, the practical challenges that remain, and the pathways through which breakthrough research in mice can translate into meaningful human therapies. His ability to inspire action whilst maintaining scientific rigour makes him invaluable for organisations seeking to understand and engage with one of the most transformative fields in modern medicine.